Location: Seattle, WA
Cap-Exempt H-1B Position — No lottery required
Overview: Fred Hutchinson Cancer Center is an independent, nonprofit organization providing adult cancer treatment and groundbreaking research focused on cancer and infectious diseases. Based in Seattle, Fred Hutch is the only National Cancer Institute-designated cancer center in Washington. With a track record of global leadership in bone marrow transplantation, HIV/AIDS prevention, immunotherapy and COVID-19 vaccines, Fred Hutch has earned a reputation as one of the world’s leading cancer, infectious disease and biomedical research centers. Fred Hutch operates eight clinical care sites that provide medical oncology, infusion, radiation, proton therapy and related services, and network affiliations with hospitals in five states. Together, our fully integrated research and clinical care teams seek to discover new cures to the world’s deadliest diseases and make life beyond cancer a reality. At Fred Hutch we value collaboration, compassion, determination, excellence, innovation, integrity and respect. Our mission is directly tied to the humanity, dignity and inherent value of each employee, patient, community member and supporter. Our commitment to learning across our differences and similarities make us stronger. We seek employees who bring different and innovative ways of seeing the world and solving problems. The **Regulatory Affairs Associate (RAA)/Regulatory Affairs Associate Sr.** is responsible for supporting investigators and staff within the Infectious Disease Sciences (IDS) Program in the Vaccine and Infectious Disease Division on regulatory issues and requirements through the full cycle of clinical trials and human subjects research. The RAA oversees communications with industry sponsors and the Fred Hutch IRB, prepares regulatory documentation, coordinates regulatory submissions and monitoring, maintains regulatory files, and facilitates regulatory oversight for all related studies. This role interacts extensively with the Institutional Review Office (IRO